These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24964950)

  • 1. The value of HIV protective epitope research for informed vaccine design against diverse viral pathogens.
    Kramer VG; Byrareddy SN
    Expert Rev Vaccines; 2014 Aug; 13(8):935-7. PubMed ID: 24964950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing antibodies and antigens in AIDS.
    Norley SG; Kurth R
    Infection; 1991; 19 Suppl 2():S83-8. PubMed ID: 1707855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoinformatic Approaches for Vaccine Designing Against Viral Infections.
    Anand R; Raghuwanshi R
    Methods Mol Biol; 2020; 2131():277-288. PubMed ID: 32162261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to induce broadly protective antibody responses to viral glycoproteins.
    Krammer F
    Expert Rev Vaccines; 2017 May; 16(5):503-513. PubMed ID: 28277797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant and epitope-based vaccines on the road to the market and implications for vaccine design and production.
    Oyarzún P; Kobe B
    Hum Vaccin Immunother; 2016 Mar; 12(3):763-7. PubMed ID: 26430814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational tools for epitope vaccine design and evaluation.
    He L; Zhu J
    Curr Opin Virol; 2015 Apr; 11():103-12. PubMed ID: 25837467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigenic Variability.
    Mosa AI
    Front Immunol; 2020; 11():2057. PubMed ID: 33013870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epitope engineering and molecular metrics of immunogenicity: a computational approach to VLP-based vaccine design.
    Joshi H; Lewis K; Singharoy A; Ortoleva PJ
    Vaccine; 2013 Oct; 31(42):4841-7. PubMed ID: 23933338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel multi-variant epitope ensemble vaccine against avian leukosis virus subgroup J.
    Wang X; Zhou D; Wang G; Huang L; Zheng Q; Li C; Cheng Z
    Vaccine; 2017 Dec; 35(48 Pt B):6685-6690. PubMed ID: 29054728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel vaccine strategies against emerging viruses.
    García-Sastre A; Mena I
    Curr Opin Virol; 2013 Apr; 3(2):210-6. PubMed ID: 23477832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The C Terminus of the Core β-Ladder Domain in Japanese Encephalitis Virus Nonstructural Protein 1 Is Flexible for Accommodation of Heterologous Epitope Fusion.
    Yen LC; Liao JT; Lee HJ; Chou WY; Chen CW; Lin YL; Liao CL
    J Virol; 2016 Feb; 90(3):1178-89. PubMed ID: 26559836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spying the neutralizing epitopes on E2 N-terminal by candidate epitope-vaccines against classical swine fever virus.
    Dong XN; Chen YH
    Vaccine; 2006 May; 24(19):4029-34. PubMed ID: 16504346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic DNA vaccine strategies against persistent viral infections.
    Villarreal DO; Talbott KT; Choo DK; Shedlock DJ; Weiner DB
    Expert Rev Vaccines; 2013 May; 12(5):537-54. PubMed ID: 23659301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Universal peptide vaccines - optimal peptide vaccine design based on viral sequence conservation.
    Toussaint NC; Maman Y; Kohlbacher O; Louzoun Y
    Vaccine; 2011 Nov; 29(47):8745-53. PubMed ID: 21875632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel combined vaccine based on monochimeric VLP co-displaying multiple conserved epitopes against enterovirus 71 and varicella-zoster virus.
    Wu Y; Zhu R; Xu L; Li Y; Li S; Yu H; Li S; Zhu H; Cheng T; Xia N
    Vaccine; 2017 May; 35(20):2728-2735. PubMed ID: 28408118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pre-existing cytotoxic T lymphocytes on therapeutic vaccines.
    Sherritt MA; Gardner J; Elliott SL; Schmidt C; Purdie D; Deliyannis G; Heath WR; Suhrbier A
    Eur J Immunol; 2000 Feb; 30(2):671-7. PubMed ID: 10671225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenic epitopes, heterologous immunity and vaccine design.
    Welsh RM; Fujinami RS
    Nat Rev Microbiol; 2007 Jul; 5(7):555-63. PubMed ID: 17558423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenic evaluation of FMD virus immuno-dominant epitopes coupled with IL-2/FcIgG in BALB/c mice.
    Doosti M; Nassiri M; Nasiri K; Tahmoorespur M; Zibaee S
    Microb Pathog; 2019 Jul; 132():30-37. PubMed ID: 31004723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of non-dominant antigens as a vaccine strategy to broaden T-cell responses during chronic viral infection.
    Holst PJ; Jensen BA; Ragonnaud E; Thomsen AR; Christensen JP
    PLoS One; 2015; 10(2):e0117242. PubMed ID: 25679375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. iVAX: An integrated toolkit for the selection and optimization of antigens and the design of epitope-driven vaccines.
    Moise L; Gutierrez A; Kibria F; Martin R; Tassone R; Liu R; Terry F; Martin B; De Groot AS
    Hum Vaccin Immunother; 2015; 11(9):2312-21. PubMed ID: 26155959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.